NEXPOVIO 20 mg, comprimé pelliculé

( ARTG ) XPOVIO is indicated:, In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior ‍‍‍‍‍‍​​​‍​​​​​​therapy., In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory medicinal product (IMiD), and an anti-CD38 monoclonal antibody (mAb).